SCNI - Scinai Immunotherapeutics Ltd.

0.7484
0.008   1.015%

Share volume: 5,412
Last Updated: 03-10-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$0.74
0.01
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-4.05%
1 Month
-6.45%
3 Months
-39.15%
6 Months
-52.63%
1 Year
-77.32%
2 Year
-85.61%
Key data
Stock price
$0.75
P/E Ratio 
0.00
DAY RANGE
$0.70 - $0.77
EPS 
N/A
52 WEEK RANGE
$0.61 - $6.18
52 WEEK CHANGE
-$77.99
MARKET CAP 
2.168 M
YIELD 
N/A
SHARES OUTSTANDING 
581.141 K
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.92
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$107,254
AVERAGE 30 VOLUME 
$51,154
Company detail
CEO: Amir Reichman
Region: US
Website: biondvax.com
Employees: 20
IPO year: 2015
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

BiondVax Pharmaceuticals Ltd. focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Recent news